Marie Hospitel

Suggest Changes

Writes About:

Learn More
PURPOSE The vascular disrupting agent ombrabulin rapidly reduces tumor blood flow and causes necrosis in vivo. A phase I dose-escalation study was designed to determine the recommended phase II dose(More)
  • 1